WO1997031110A1 - Molecule de la famille des genes de transfert f, polynucleotide codant pour cette molecule et anticorps actif contre cette molecule - Google Patents
Molecule de la famille des genes de transfert f, polynucleotide codant pour cette molecule et anticorps actif contre cette molecule Download PDFInfo
- Publication number
- WO1997031110A1 WO1997031110A1 PCT/JP1997/000512 JP9700512W WO9731110A1 WO 1997031110 A1 WO1997031110 A1 WO 1997031110A1 JP 9700512 W JP9700512 W JP 9700512W WO 9731110 A1 WO9731110 A1 WO 9731110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecule
- traf
- family
- leu
- traf family
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 73
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 73
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 73
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 28
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 22
- 108020004414 DNA Proteins 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 150000001413 amino acids Chemical group 0.000 claims description 19
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 16
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 16
- 230000004568 DNA-binding Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 10
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 101150013553 CD40 gene Proteins 0.000 claims description 9
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 9
- 101710096438 DNA-binding protein Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 40
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 abstract description 22
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 abstract description 20
- 239000000523 sample Substances 0.000 abstract description 20
- 230000006870 function Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 6
- 239000003155 DNA primer Substances 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 108020004635 Complementary DNA Proteins 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 52
- 239000002299 complementary DNA Substances 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 39
- 239000000203 mixture Substances 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 26
- 239000013598 vector Substances 0.000 description 26
- 239000013615 primer Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 230000027455 binding Effects 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 239000012528 membrane Substances 0.000 description 13
- 101150096316 5 gene Proteins 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 101100370312 Homo sapiens TRAF5 gene Proteins 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 description 10
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 description 10
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 9
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 102000005720 Glutathione transferase Human genes 0.000 description 8
- 108010070675 Glutathione transferase Proteins 0.000 description 8
- 101100370313 Mus musculus Traf5 gene Proteins 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 5
- 101000830930 Homo sapiens TNF receptor-associated factor 5 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 108010016616 cysteinylglycine Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 4
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- 102000055263 human TRAF5 Human genes 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000005185 salting out Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- IICZCLFBILYRCU-WHFBIAKZSA-N Asn-Gly-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IICZCLFBILYRCU-WHFBIAKZSA-N 0.000 description 3
- VRJZMZGGAKVSIQ-SRVKXCTJSA-N Cys-Tyr-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VRJZMZGGAKVSIQ-SRVKXCTJSA-N 0.000 description 3
- 108020001019 DNA Primers Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 3
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 3
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 3
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 3
- NLWCSMOXNKBRLC-WDSOQIARSA-N Trp-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLWCSMOXNKBRLC-WDSOQIARSA-N 0.000 description 3
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108010060199 cysteinylproline Proteins 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 3
- 108010025306 histidylleucine Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000010841 mRNA extraction Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 108010018625 phenylalanylarginine Proteins 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- KGSJCPBERYUXCN-BPNCWPANSA-N Arg-Ala-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KGSJCPBERYUXCN-BPNCWPANSA-N 0.000 description 2
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 2
- KZXPVYVSHUJCEO-ULQDDVLXSA-N Arg-Phe-Lys Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 KZXPVYVSHUJCEO-ULQDDVLXSA-N 0.000 description 2
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 2
- RFLVTVBAESPKKR-ZLUOBGJFSA-N Asn-Cys-Cys Chemical compound N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O RFLVTVBAESPKKR-ZLUOBGJFSA-N 0.000 description 2
- BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 2
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 2
- KVPHTGVUMJGMCX-BIIVOSGPSA-N Asp-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N)C(=O)O KVPHTGVUMJGMCX-BIIVOSGPSA-N 0.000 description 2
- HSPSXROIMXIJQW-BQBZGAKWSA-N Asp-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 HSPSXROIMXIJQW-BQBZGAKWSA-N 0.000 description 2
- VSMYBNPOHYAXSD-GUBZILKMSA-N Asp-Lys-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O VSMYBNPOHYAXSD-GUBZILKMSA-N 0.000 description 2
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 2
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 108091028026 C-DNA Proteins 0.000 description 2
- HRJLVSQKBLZHSR-ZLUOBGJFSA-N Cys-Asn-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O HRJLVSQKBLZHSR-ZLUOBGJFSA-N 0.000 description 2
- ZOKPRHVIFAUJPV-GUBZILKMSA-N Cys-Pro-Arg Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O ZOKPRHVIFAUJPV-GUBZILKMSA-N 0.000 description 2
- MBRWOKXNHTUJMB-CIUDSAMLSA-N Cys-Pro-Glu Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O MBRWOKXNHTUJMB-CIUDSAMLSA-N 0.000 description 2
- XBELMDARIGXDKY-GUBZILKMSA-N Cys-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)N XBELMDARIGXDKY-GUBZILKMSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- RDDSZZJOKDVPAE-ACZMJKKPSA-N Glu-Asn-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDDSZZJOKDVPAE-ACZMJKKPSA-N 0.000 description 2
- OHWJUIXZHVIXJJ-GUBZILKMSA-N Glu-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N OHWJUIXZHVIXJJ-GUBZILKMSA-N 0.000 description 2
- BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 description 2
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 2
- LHRXAHLCRMQBGJ-RYUDHWBXSA-N Gly-Glu-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN LHRXAHLCRMQBGJ-RYUDHWBXSA-N 0.000 description 2
- TVDHVLGFJSHPAX-UWVGGRQHSA-N Gly-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 TVDHVLGFJSHPAX-UWVGGRQHSA-N 0.000 description 2
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 2
- GWNIGUKSRJBIHX-STQMWFEESA-N Gly-Tyr-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)CN)O GWNIGUKSRJBIHX-STQMWFEESA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- LVXFNTIIGOQBMD-SRVKXCTJSA-N His-Leu-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O LVXFNTIIGOQBMD-SRVKXCTJSA-N 0.000 description 2
- JGFWUKYIQAEYAH-DCAQKATOSA-N His-Ser-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JGFWUKYIQAEYAH-DCAQKATOSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 2
- IIKJNQWOQIWWMR-CIUDSAMLSA-N Leu-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N IIKJNQWOQIWWMR-CIUDSAMLSA-N 0.000 description 2
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 2
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 2
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 2
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 2
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 2
- DDVHDMSBLRAKNV-IHRRRGAJSA-N Leu-Met-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O DDVHDMSBLRAKNV-IHRRRGAJSA-N 0.000 description 2
- RDFIVFHPOSOXMW-ACRUOGEOSA-N Leu-Tyr-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RDFIVFHPOSOXMW-ACRUOGEOSA-N 0.000 description 2
- QUYCUALODHJQLK-CIUDSAMLSA-N Lys-Asp-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUYCUALODHJQLK-CIUDSAMLSA-N 0.000 description 2
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 2
- DAOSYIZXRCOKII-SRVKXCTJSA-N Lys-His-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O DAOSYIZXRCOKII-SRVKXCTJSA-N 0.000 description 2
- OIYWBDBHEGAVST-BZSNNMDCSA-N Lys-His-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OIYWBDBHEGAVST-BZSNNMDCSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 2
- MHNBYYFXWDUGBW-RPTUDFQQSA-N Phe-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O MHNBYYFXWDUGBW-RPTUDFQQSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- JJKSSJVYOVRJMZ-FXQIFTODSA-N Ser-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)CN=C(N)N JJKSSJVYOVRJMZ-FXQIFTODSA-N 0.000 description 2
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 2
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 2
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 description 2
- 102000003715 TNF receptor-associated factor 4 Human genes 0.000 description 2
- 108090000008 TNF receptor-associated factor 4 Proteins 0.000 description 2
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- GFUOTIPYXKAPAH-BVSLBCMMSA-N Trp-Pro-Phe Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GFUOTIPYXKAPAH-BVSLBCMMSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- FFCRCJZJARTYCG-KKUMJFAQSA-N Tyr-Cys-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N)O FFCRCJZJARTYCG-KKUMJFAQSA-N 0.000 description 2
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 2
- OJPRSVJGNCAKQX-SRVKXCTJSA-N Val-Met-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N OJPRSVJGNCAKQX-SRVKXCTJSA-N 0.000 description 2
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- BOKLLPVAQDSLHC-FXQIFTODSA-N Ala-Val-Cys Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N BOKLLPVAQDSLHC-FXQIFTODSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 1
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- QAXCZGMLVICQKS-SRVKXCTJSA-N Arg-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N QAXCZGMLVICQKS-SRVKXCTJSA-N 0.000 description 1
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 1
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 1
- AKEBUSZTMQLNIX-UWJYBYFXSA-N Asn-Ala-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N AKEBUSZTMQLNIX-UWJYBYFXSA-N 0.000 description 1
- OGMDXNFGPOPZTK-GUBZILKMSA-N Asn-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N OGMDXNFGPOPZTK-GUBZILKMSA-N 0.000 description 1
- QEQVUHQQYDZUEN-GUBZILKMSA-N Asn-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N QEQVUHQQYDZUEN-GUBZILKMSA-N 0.000 description 1
- HXWUJJADFMXNKA-BQBZGAKWSA-N Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O HXWUJJADFMXNKA-BQBZGAKWSA-N 0.000 description 1
- GLWFAWNYGWBMOC-SRVKXCTJSA-N Asn-Leu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GLWFAWNYGWBMOC-SRVKXCTJSA-N 0.000 description 1
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- KWBQPGIYEZKDEG-FSPLSTOPSA-N Asn-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O KWBQPGIYEZKDEG-FSPLSTOPSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- QCLHLXDWRKOHRR-GUBZILKMSA-N Asp-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N QCLHLXDWRKOHRR-GUBZILKMSA-N 0.000 description 1
- VIRHEUMYXXLCBF-WDSKDSINSA-N Asp-Gly-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O VIRHEUMYXXLCBF-WDSKDSINSA-N 0.000 description 1
- CRNKLABLTICXDV-GUBZILKMSA-N Asp-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N CRNKLABLTICXDV-GUBZILKMSA-N 0.000 description 1
- LNENWJXDHCFVOF-DCAQKATOSA-N Asp-His-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N LNENWJXDHCFVOF-DCAQKATOSA-N 0.000 description 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 1
- GWWSUMLEWKQHLR-NUMRIWBASA-N Asp-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GWWSUMLEWKQHLR-NUMRIWBASA-N 0.000 description 1
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077333 CAP1-6D Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 101100521925 Chlorobium chlorochromatii (strain CaD3) psd gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- DCJNIJAWIRPPBB-CIUDSAMLSA-N Cys-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N DCJNIJAWIRPPBB-CIUDSAMLSA-N 0.000 description 1
- JTNKVWLMDHIUOG-IHRRRGAJSA-N Cys-Arg-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JTNKVWLMDHIUOG-IHRRRGAJSA-N 0.000 description 1
- KCPOQGRVVXYLAC-KKUMJFAQSA-N Cys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CS)N KCPOQGRVVXYLAC-KKUMJFAQSA-N 0.000 description 1
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 1
- CAXGCBSRJLADPD-FXQIFTODSA-N Cys-Pro-Asn Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O CAXGCBSRJLADPD-FXQIFTODSA-N 0.000 description 1
- KVCJEMHFLGVINV-ZLUOBGJFSA-N Cys-Ser-Asn Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KVCJEMHFLGVINV-ZLUOBGJFSA-N 0.000 description 1
- IWVNIQXKTIQXCT-SRVKXCTJSA-N Cys-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CS)N)O IWVNIQXKTIQXCT-SRVKXCTJSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 1
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 1
- GTFYQOVVVJASOA-ACZMJKKPSA-N Glu-Ser-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N GTFYQOVVVJASOA-ACZMJKKPSA-N 0.000 description 1
- JVYNYWXHZWVJEF-NUMRIWBASA-N Glu-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O JVYNYWXHZWVJEF-NUMRIWBASA-N 0.000 description 1
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- GVVKYKCOFMMTKZ-WHFBIAKZSA-N Gly-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CN GVVKYKCOFMMTKZ-WHFBIAKZSA-N 0.000 description 1
- VNBNZUAPOYGRDB-ZDLURKLDSA-N Gly-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)O VNBNZUAPOYGRDB-ZDLURKLDSA-N 0.000 description 1
- NTOWAXLMQFKJPT-YUMQZZPRSA-N Gly-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN NTOWAXLMQFKJPT-YUMQZZPRSA-N 0.000 description 1
- QSVMIMFAAZPCAQ-PMVVWTBXSA-N Gly-His-Thr Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QSVMIMFAAZPCAQ-PMVVWTBXSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
- LBCAQRFTWMMWRR-CIUDSAMLSA-N His-Cys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O LBCAQRFTWMMWRR-CIUDSAMLSA-N 0.000 description 1
- IMCHNUANCIGUKS-SRVKXCTJSA-N His-Glu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IMCHNUANCIGUKS-SRVKXCTJSA-N 0.000 description 1
- XMENRVZYPBKBIL-AVGNSLFASA-N His-Glu-His Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O XMENRVZYPBKBIL-AVGNSLFASA-N 0.000 description 1
- XKIYNCLILDLGRS-QWRGUYRKSA-N His-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 XKIYNCLILDLGRS-QWRGUYRKSA-N 0.000 description 1
- CKRJBQJIGOEKMC-SRVKXCTJSA-N His-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CKRJBQJIGOEKMC-SRVKXCTJSA-N 0.000 description 1
- VXZZUXWAOMWWJH-QTKMDUPCSA-N His-Thr-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VXZZUXWAOMWWJH-QTKMDUPCSA-N 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- YOZCKMXHBYKOMQ-IHRRRGAJSA-N Leu-Arg-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOZCKMXHBYKOMQ-IHRRRGAJSA-N 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 1
- INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- SXOFUVGLPHCPRQ-KKUMJFAQSA-N Leu-Tyr-Cys Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(O)=O SXOFUVGLPHCPRQ-KKUMJFAQSA-N 0.000 description 1
- VQHUBNVKFFLWRP-ULQDDVLXSA-N Leu-Tyr-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=C(O)C=C1 VQHUBNVKFFLWRP-ULQDDVLXSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- CLBGMWIYPYAZPR-AVGNSLFASA-N Lys-Arg-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O CLBGMWIYPYAZPR-AVGNSLFASA-N 0.000 description 1
- GAOJCVKPIGHTGO-UWVGGRQHSA-N Lys-Arg-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O GAOJCVKPIGHTGO-UWVGGRQHSA-N 0.000 description 1
- FUKDBQGFSJUXGX-RWMBFGLXSA-N Lys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)O FUKDBQGFSJUXGX-RWMBFGLXSA-N 0.000 description 1
- HQVDJTYKCMIWJP-YUMQZZPRSA-N Lys-Asn-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HQVDJTYKCMIWJP-YUMQZZPRSA-N 0.000 description 1
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 1
- SSYOBDBNBQBSQE-SRVKXCTJSA-N Lys-Cys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O SSYOBDBNBQBSQE-SRVKXCTJSA-N 0.000 description 1
- KZOHPCYVORJBLG-AVGNSLFASA-N Lys-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N KZOHPCYVORJBLG-AVGNSLFASA-N 0.000 description 1
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 1
- ALGGDNMLQNFVIZ-SRVKXCTJSA-N Lys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ALGGDNMLQNFVIZ-SRVKXCTJSA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- MTBLFIQZECOEBY-IHRRRGAJSA-N Lys-Met-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O MTBLFIQZECOEBY-IHRRRGAJSA-N 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 1
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- BVXXDMUMHMXFER-BPNCWPANSA-N Met-Ala-Tyr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVXXDMUMHMXFER-BPNCWPANSA-N 0.000 description 1
- WDTLNWHPIPCMMP-AVGNSLFASA-N Met-Arg-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O WDTLNWHPIPCMMP-AVGNSLFASA-N 0.000 description 1
- KRLKICLNEICJGV-STQMWFEESA-N Met-Phe-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 KRLKICLNEICJGV-STQMWFEESA-N 0.000 description 1
- ZGVYWHODYWRPLK-GUBZILKMSA-N Met-Pro-Cys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O ZGVYWHODYWRPLK-GUBZILKMSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- YYRCPTVAPLQRNC-ULQDDVLXSA-N Phe-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC1=CC=CC=C1 YYRCPTVAPLQRNC-ULQDDVLXSA-N 0.000 description 1
- OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- DNAXXTQSTKOHFO-QEJZJMRPSA-N Phe-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DNAXXTQSTKOHFO-QEJZJMRPSA-N 0.000 description 1
- DMEYUTSDVRCWRS-ULQDDVLXSA-N Phe-Lys-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DMEYUTSDVRCWRS-ULQDDVLXSA-N 0.000 description 1
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
- CDHURCQGUDNBMA-UBHSHLNASA-N Phe-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 CDHURCQGUDNBMA-UBHSHLNASA-N 0.000 description 1
- IEIFEYBAYFSRBQ-IHRRRGAJSA-N Phe-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N IEIFEYBAYFSRBQ-IHRRRGAJSA-N 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- NHDVNAKDACFHPX-GUBZILKMSA-N Pro-Arg-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O NHDVNAKDACFHPX-GUBZILKMSA-N 0.000 description 1
- VPVHXWGPALPDGP-GUBZILKMSA-N Pro-Asn-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPVHXWGPALPDGP-GUBZILKMSA-N 0.000 description 1
- WWAQEUOYCYMGHB-FXQIFTODSA-N Pro-Asn-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 WWAQEUOYCYMGHB-FXQIFTODSA-N 0.000 description 1
- FUVBEZJCRMHWEM-FXQIFTODSA-N Pro-Asn-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FUVBEZJCRMHWEM-FXQIFTODSA-N 0.000 description 1
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 1
- AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- JEHPKECJCALLRW-CUJWVEQBSA-N Ser-His-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEHPKECJCALLRW-CUJWVEQBSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- PRNGXSILMXSWQQ-OEAJRASXSA-N Thr-Leu-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PRNGXSILMXSWQQ-OEAJRASXSA-N 0.000 description 1
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- ZAGPDPNPWYPEIR-SRVKXCTJSA-N Tyr-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ZAGPDPNPWYPEIR-SRVKXCTJSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 1
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- LJSZPMSUYKKKCP-UBHSHLNASA-N Val-Phe-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 LJSZPMSUYKKKCP-UBHSHLNASA-N 0.000 description 1
- YQMILNREHKTFBS-IHRRRGAJSA-N Val-Phe-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N YQMILNREHKTFBS-IHRRRGAJSA-N 0.000 description 1
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- -1 X—Ga1 Chemical compound 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000004712 monophosphates Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010031970 prostasin Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 108010001055 thymocartin Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- TRAF family molecules polynucleotides encoding the molecules, and antibodies against the molecules
- the present invention relates to TRAF family molecules, polynucleotides encoding the molecules, antibodies against the molecules, and antisense polynucleotides of the polynucleotides encoding the molecules.
- TNF-R TNF receptor
- TNF-R2 TNF-R2
- Fas CD40
- CD27 CD27
- lymphotoxin-1 / 3 receptor lymphotoxin-1 / 3 receptor
- TRAF 1 abbreviation of TNF-R associated factor (TNF-R associated molecule)
- TRAF 2 which are molecules that associate with TNF-R, are cloned (Go eddel et al., Cellvol. 78 No. 4). 681-692, 1994), which are known to associate with the cytoplasmic domain of TNF-R2.
- TRAF 1 must associate with TNF-R2 and CD40 (J. Biol. Chem. Vol. 269 No. 48, p. 30069 to 30072),
- TRAF 2 is NF- / c B (immunoglobulin ⁇ It plays an important role in activating the DNA binding of a nucleoprotein that binds to a base sequence consisting of 10 base pairs called the / cB motif in the enhancer region of the L chain gene,
- TRAF 3 (also called CRAF 1, CD40bp or CAP1) is known to associate with TNF-R2, CD40 and LT- / 3R (
- TRAF4 also called CART 1
- CART 1 For TRAF4 (also called CART 1), no associated molecule has yet been identified (J. Biol. Chem. Vol. 270 No. 43, p. 25715-25721, 1 995).
- the molecules of the TRAF family are structurally characterized by having a TRAF domain, and depending on the family member, the RING finger motif, Zn finger motif, leucine zipper motif, etc. Or it has a coiled coil structure in the center. From these structural and usual characteristics, it is speculated that these TRAF family molecules form homo- or hetero-complexes and function as transcription factors. Disclosure of the invention
- An object of the present invention is to provide a new molecule of the TRAF family. Also, The present invention is applied to elucidation of the function of one molecule of the TRAF family, such as an antibody or a polynucleotide probe, that is, to elucidation of the interaction between one molecule of the TRAF family and the signal transduction system of the TNF-R family. The challenge is to provide substances that can be used. Furthermore, an object of the present invention is to provide an antisense polynucleotide applicable to drug development.
- an object of the present invention is to search, isolate, and structurally identify a TRAF 5 molecule, which is a novel TRAF family molecule according to the present invention, and to provide various functions of the molecule.
- the present invention provides a computer analysis of the homology of TRAF 1 and TRAF 2, synthesis of various oligo DNA primers capable of amplifying the most conserved region, and generation of various DNA-derived primers.
- New DNA showing high homology with TRAF1 and TRAF2 genes, obtained by preparing cDNA based on RNA and performing PCR using oligoDNA primers with cDNA as type II It is an object of the present invention to provide a gene (TRAF 5 gene) and an amino acid sequence of 5 molecules of TRAF encoded by the gene.
- TRAF 5 molecule the protein is hereinafter referred to as TRAF 5 molecule or TRAF 5
- TRAF 5 gene itself is referred to as TRAF 5 gene.
- Another object is to provide a finding that TRAF 5 molecules are associated with LT- / 3R and CD30, and that TRAF 5 molecules have the inducibility of DNA binding activity of NF- / cB, a DNA-binding protein.
- an antibody against the TRAF 5 molecule is prepared, and the antibody provides a means for elucidating the function of the TRAF 5 molecule and a means for elucidating the signal transduction system of the TNF-R family involved in the TRAF family molecule. That is the task.
- TRAF family molecules having the following properties (1) to (4):
- lymphotoxin-1) 3 receptor (LT-) 3R) and CD30 It has an association with lymphotoxin-1) 3 receptor (LT-) 3R) and CD30.
- TRAF family molecule described above, wherein the DNA-binding protein is NF- ⁇ B.
- TRAF family which is a protein encoded by DNA that hybridizes under stringent conditions with the nucleotide sequence of SEQ ID NO: 2 in the sequence listing.
- TRAF family molecule having at least a part of the amino acid sequence of SEQ ID NO: 1 or 3 in the sequence listing.
- TRAF molecules comprising the amino acid sequence of SEQ ID NO: 1 in the sequence listing.
- TRAF 5 molecule comprising the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing.
- TRAF 5 molecule comprising the amino acid sequence of SEQ ID NO: 1 or 3 in the BB column list, wherein the TRAF family molecule has one or more of the above-mentioned amino acid sequences without substantially changing the function of the TRAF family molecule.
- TRAF family molecules whose parts have been modified by amino acid substitutions, deletions or additions.
- a TRAF 5 molecule comprising an amino acid sequence from position 233 to position 558 of the amino acid sequence described in SEQ ID NO: 1 in the sequence listing.
- a TRAF 5 molecule comprising an amino acid sequence from position 342 to position 558 of the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing.
- a TRAF 5 molecule comprising the amino acid sequence from position 233 to position 557 of the amino acid sequence described in SEQ ID NO: 3 in the sequence listing.
- TRAF family molecule described above.
- TRAF 5 gene consisting of the nucleotide sequence of SEQ ID NO: 2 in the sequence listing.
- TRAF5 gene consisting of the nucleotide sequence of SEQ ID NO: 4 in the sequence listing.
- a polynucleotide which is a part of continuous 12 or more bases of the polynucleotide according to any of 12 to 14 above.
- a polynucleotide which is a part of 16 or more consecutive bases of the polynucleotide according to any of 12 to 14 above.
- An expression vector comprising a polynucleotide encoding one TRAF family molecule of the above item 12.
- a transformant characterized by being transformed with the expression vector.
- a method for producing a TRAF family molecule comprising using the transformant.
- FIG. 1 shows the results of homology analysis of the amino acid sequences of 5 molecules of mouse TRAF and one molecule of another TRAF family.
- the black part is TR A
- the F domain (TRAF domain) indicates the leucine zipper motif (Leucine Zipper)
- the hatched region indicates the Zn finger motif (Zinc finger)
- the horizontal line indicates the region. It represents the RING finger motif (Zinc ring finger).
- TRAF 1 to TRAF 4 the full length (overall) with TRAF 5 and the homology of amino acids in the TRAF domain (TRAF domain) are shown on the right side.
- FIG. 2 is a photograph showing the results of Northern blot hybridization analysis of each tissue of the mouse TRAF5 gene.
- the arrow indicates the position of the mouse TRAF5 gene band.
- FIG. 3 is a photograph showing the results of SDS-PAGE of searching for one molecule of TNF-R family associated with five molecules of mouse TRAF.
- the arrow indicates the position of the band of the mouse TRAF 5 molecule.
- FIG. 4 is a photograph showing the results of immunoprecipitation western blotting of the aggregated substance of mouse TRAF 5 molecules and LT- ⁇ R using HA epitope.
- the arrow indicates the position of the mouse TRAF 5 molecule to which the peptide was bound.
- Figure 5 is a photograph showing the results of EMS Alpha indicating the DN Alpha binding activity inducing NF-? Kappa B by murine TRAF 5 molecules or LT one j3 R molecule.
- B ⁇ the position of the indicated bands NF-? Kappa B, the density of the bands indicates the amount of DNA bound to NF-? Kappa beta.
- FIG. 6D shows primers used for identification of the mouse TRAF5 gene.
- FIG. 6B is a diagram showing primers used for identification of mouse TRAF5 gene.
- Figure 8 shows Cys Tyr Ser Gly Lys Leu lie Trp Lvs Val Thr Asp Tyr Arg (CYSGKL I WKVTDYR) from position 401 to position 4 of mouse TRAF 5 molecule.
- 14 is a graph showing the result of ELISA of a polyclonal antibody against the 14mer peptide (peptide of sequence 2).
- FIG. 9 is a photograph of a western blot showing the expression of five human TRAF molecules in each cell line. The arrow indicates the position of the band of the human TRAF 5 molecule.
- FIG. 10 is a photograph showing the association of CD30 or LT-3R with 5 mouse TRAF molecules, 2 mouse TRAF molecules or 3 mouse TRAF molecules. Arrows indicate the positions of the bands of mouse TRAF 2 molecules, mouse TRAF 3 molecules or mouse TRAF 5 molecules.
- FIG. 11 shows a comparison of the amino acid sequences of five human TRAF molecules and five mouse TRAF molecules.
- the upper row shows the amino acid sequence of human TRAF5, and the lower row shows the amino acid sequence of mouse TRAF5.
- One in the mouse TRAF5 sequence indicates that the amino acid at that position is the same as the corresponding amino acid in human TRAF5 (ie, the amino acid described at the top).
- the one at position 494 in the sequence of human TRAF5 indicates that the amino acid at that position is missing.
- the method for identifying a TRAF family molecule according to the present invention and a polynucleotide encoding one molecule of the TRAF family of the present invention will be specifically described below.
- a homology search is performed on the known base E sequence of TRAF1 and TRAF2, and a region with the highest homology between the two is identified and selected.
- a primer is designed for PCR amplification (polymerase chain reaction) of the specified region.
- the nucleotide sequence of the target primer is not particularly limited. In the present invention, for example, as shown in FIGS. A mixture of primers to which an I site has been added can be preferably used. Further, such primers can be synthesized using a conventional DNA synthesizer.
- A is adenine
- T is thymine
- G is guanine
- C is cytosine
- Y is cytosine or thymine
- N is adenine, thymine, guanine or cytosine
- R is adenine or guanine
- D is adenine, thymine or guanine. Therefore, (1) in FIG. 6A represents 256 primers, and (2) in FIG. 6B represents 768 primers.
- mRNA is prepared from mouse B cell lymphoma, mouse monocyte cell line and mouse liver, and oligo d is prepared.
- cDNA is prepared using T or random hexamers as primers.
- cells for the purpose of adjusting the mRNA are not limited to the above cells.
- RNA fraction for example, after obtaining a total RNA fraction by the guanidine thiocyanate method (“Biochemistryvol. 13” p. 2633, 1974), an oligo (dT) cellulose column or the like is used. It is possible to carry out the preparation appropriately.
- the obtained cDNA template was used as a type II, PCR was performed using the above primers, the amplified fragment was recovered, and a closing vector having a multiple cloning site (for example, pBluescript SK (+) Is preferably used).
- the subcloned product is subjected to a DNA sequence using the DNA sequencer by a didoxy method, and is found to be a novel gene. With this method, a new TRAF family gene fragment is obtained. This new TRAF family gene is labeled with 32 P to give a 32 P—TRAF fragment.
- RNA is newly prepared from a monocyte cell line or a tissue such as liver tissue, and a cDNA library is prepared therefrom.
- a cDNA library is prepared therefrom.
- phage vectors such as AgtlO, ⁇ gt11 and ⁇ ZAP11, as well as plasmid vectors such as pBR and pUC can be used.
- the thus prepared cDNA library is subjected to screening using the aforementioned 32 P-TRAF fragment as a probe to obtain a clone containing cDNA covering the entire translation region of TRAF5.
- the nucleotide sequence is determined using a DNA sequencer.
- the TRAF5 gene of other animals including humans can be obtained from cells of the target animal species.
- search and acquisition can be performed in the same manner as described above.
- TRAF5 The structure of the TRAF5 gene, for example, in the case of a mouse, is as shown in SEQ ID NO: 2 in the sequence listing.
- Mouse TRAF5 consists of an open reading frame of 1674 nucleotides (positions 323 to 1999 of the sequence number in the sequence listing) and is composed of 558 amino acids. Its mRNA size is assumed to be 2.2 kb.
- the amino acid sequence of 5 mouse TRAF molecules encoded by the above nucleotide sequence is shown in SEQ ID NO: 1 in the sequence listing. Referring to FIG. 1, the amino acid sequence is compared to known TRAF family molecules. Structurally, the TRAF 5 molecule is similar to the TRAF 3 molecule. TRAF5 molecules differ from TRAF1, TRAF2 and TRAF4 molecules in having a leucine zipper motif or coiled coil structure.
- the amino acid sequences of the mouse TRAF 5 molecule and the human TRAF 5 molecule are very homologous, and their functions are well conserved between different types. Therefore, the TRAF5 gene shows high homology in mice and humans, and the plaque hybridization was carried out using the method of Example 7 described later, ie, using all or a part of the already obtained TRAF5 gene as a probe. Isolating the TRAF5 gene of the target animal from a cDNA library derived from the target animal by a commonly used cDNA library method such as the cDNA method. You can get a message.
- a molecule of the TNF-R family of the present invention, in which five TRAF molecules have association properties, can be searched, for example, by the following method.
- a fusion protein is prepared using a fusion protein expression system.
- a method in which a fusion protein is prepared by inserting a portion of the cytoplasmic domain of a TNF-R family molecule into the downstream of daltathione-1 S-transferase (GST) can be preferably used.
- GST daltathione-1 S-transferase
- any protein that can synthesize a fusion protein with a TNF-R family molecule besides GST can be used.
- a thioredoxin fusion protein of ThioFusion registered trademark, manufactured by Invitrogen
- a fusion protein expression system with a leader peptide derived from gene 10 of T7 can be used.
- the TRAF 5 gene is translated in vitro, and 5 molecules of TRAF labeled with 35 S-methionine or the like are prepared. It is possible to do it.
- the fusion protein and 5 TRAF molecules are mixed to select a fusion protein associated with the 5 TRAF molecules.
- a selection method for example, a method in which an associated substance is adsorbed on a GSH-agarose column can be used.
- chromatography such as affinity chromatography can be preferably used.
- the above-mentioned associated substance is separated, heat is applied to dissociate the TRAF 5 molecules, SDS-PAGE is performed, and the gel is subjected to autoradiography.
- SDS-PAGE is performed, and the gel is subjected to autoradiography.
- the TRAF 5 molecule band it is possible to confirm that the TRAF 5 molecule has an association with LT- ⁇ R and CD30.
- the association between the TRAF 5-molecule and LT-1) 3R was determined by immunoprecipitation Western blotting. It is also possible to confirm the nature.
- the TRAF 5 molecule used binds the influenza virus hemagglutinin epitope (HA epitope) as a tag.
- the aforementioned method of binding a leader peptide derived from the T7 gene 10 can be preferably used.
- various known methods can be used for the tag binding method.
- a genetic engineering method is preferable. In particular, treatment with a restriction enzyme such as EcoRI is carried out, and the HA peptide is used. It is preferred to incorporate into the expression vector a DNA encoding the gene and TRAF 5 molecules amplified by PCR.
- the TRAF 5 molecule when the TRAF 5 molecule is produced by a gene engineering method, it is preferable to introduce a TRAF 5 molecule expression vector and an LT1 / 3R-introduced vector into a cell.
- a method for introducing the vector into a cell a liposomal method, an electoral portation method, or the like can be used.
- a DEAE-dextran method Pharmacia
- the TRAF 5 molecule and the substance associated with the TRAF 5 molecule can be accurately determined. It is possible to separate and collect.
- the TRAF 5 molecule of the present invention has an associating property with LT-3R and CD30, which are one molecule of the TNF-R family, and this property is a function of the molecule of the TNF-R family. It can be used to elucidate.
- the TNF-R family molecule and one member of the TNF family are important molecules that trigger intracellular differentiation, proliferation, and death. Using antibodies and the like, it will be possible to elucidate such functions and elucidate the mechanisms of cancer and apoptosis.
- LT-1 / 3R like LT-1 ⁇ , is estimated to have an important role in immune system differentiation.
- peripheral lymph node differentiation is immature in mice lacking the gene for LT-1 ⁇ , and it is considered that LT-) 3R is similar.
- CD30 the function of CD30 is that T cells cannot be normally differentiated in the thymus in deficient mice, and that signals mediated by T cell receptors are not transmitted well. Therefore, the association of the TRAF 5 molecule with the LT-j3R or CD30 suggests that the TRAF 5 molecule should be a key substance in LT / 1/3 R signaling, It is presumed that mice lacking cause immaturity of the immune system, for example, immature differentiation of peripheral lymph nodes.
- the expression of the TRAF 5 molecule induces the DNA binding protein NF- ⁇ B DNA binding activation. Can be confirmed. That is, it is confirmed that the TRAF5 molecule can be used for inducing DNA binding activation of a DNA binding protein.
- the expression of NF- ⁇ B is caused only by the expression of LT-3R, but the 233rd position to the 233rd position of the mouse TRAF 5 molecule, which is a deleted protein. It can be confirmed that the activation is suppressed by adding only the 558th position in excess.
- the use of positions 233 to 558 of the TRAF 5 molecule makes it possible to study the effect of antagonizing LT-1) 3R.
- the present invention makes it possible to study a system for controlling signal transduction involving NF- ⁇ or to develop a drug by adjusting the TRAF 5 molecule or the TRAF 5 gene according to the present invention.
- NF- ⁇ binding to the probe was generated using a TRAF 5 molecule.
- a method of detecting from the expressed cells can be used.
- the TRAF 5 molecules used may be all or part.
- NF-? Kappa in gene itself polynucleotide probe is NF-? / C beta comprising a binding site of the B, may even partially, be of natural, or may be one synthesized.
- an electrogel shift method ⁇ 1 ectrophoretic mobility shift as say (EMS A)
- a gel shift method can be used.
- one molecule of the TRAF family of the present invention has a property capable of associating with LT-R and CD30 and inducing the DNA binding activity of a DNA-binding protein.
- NF- ⁇ B is preferable as the DNA binding protein for confirming the induction of DNA binding activity.
- lymphotoxin-1) 3 receptor (LT-3R) and CD30 has an association with lymphotoxin-1) 3 receptor (LT-3R) and CD30.
- the TRAF family molecules of the present invention include those having at least a part of the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3 in the sequence listing as long as they have the above properties. Part of the above amino acid sequence is not particularly limited. It is preferably at positions 233 to 558 of the amino acid sequence of SEQ ID NO: 1. In particular, it preferably has a TRAF domain (positions 342 to 558 in the amino acid sequence of SEQ ID NO: 1 in the sequence listing).
- the TRAF family molecule of the present invention has the above-mentioned properties, as shown in Example 7, the molecule is hybridized to a DNA that hybridizes to a part of the nucleotide sequence shown in SEQ ID NO: 2 in the sequence listing. And proteins to be loaded.
- a TRAF family molecule of the present invention may be structurally modified by substituting, deleting or adding an amino acid to a part of the above TRAF family molecule.
- Known methods can be used for the method of substituting, deleting or adding amino acids. For example, "Molecu lar Cloning"
- the polynucleotide encoding one molecule of the TRAF family of the present invention is, for example, a DNA consisting of the nucleotide sequence from position 323 to position 1999 of the nucleotide sequence of SEQ ID NO: 2 in the sequence listing, and an RNA corresponding to the DNA.
- These are polynucleotides encoding the mouse TRAF 5 molecule consisting of the amino acid sequence of SEQ ID NO: 1 in the sequence listing, and expressing all or a part of the coding region of the protein in an appropriate transformant. It can be used to produce recombinant TRAF family members.
- a part of the polynucleotide can be used immediately as a research polynucleotide probe for examining the presence or expression of a gene encoding a single TRAF family molecule in a tissue or a cell.
- the part used as a probe is preferably one having 12 bases or more and having a GC content of 30 to 70%. It is particularly preferable if the number is 16 bases or more.
- the polynucleotide used as a probe may be a derivative. For use as a probe, it may be a nucleotide sequence of a non-coding region of a gene encoding one TRAF family molecule or a nucleotide sequence complementary thereto. (TRAF family antibody of the present invention)
- the TRAF family molecular antibody of the present invention includes both polyclonal antibodies and monoclonal antibodies as long as it recognizes one TRAF family molecule molecule of the present invention. Also included are active fragments thereof and chimeric antibodies containing the active fragments. Antibodies, ie, immunoglobulins, have heavy and light chains and are divided into five classes (IgA, IgD, IgE, IgG, IgM) based on their physicochemical and immunological properties. Of these, IgA and IgG are further divided into subclasses depending on the type of H chain. The novel antibodies of the present invention include those belonging to all these classes and subclasses.
- the antibody of the present invention does not necessarily need to use the entire antibody molecule, and can use a part of the molecule (active fraction) as long as it has activity.
- specific examples of the active fragment include F (ab ′) 2, Fab, Fv and recombinant Fv.
- digestion with pepsin yields F (ab ') 2
- digestion with papain yields Fab.
- active fragments can be used alone or, if necessary, combined with a substance such as albumin or polyethylene glycol to be used as a new complex. In general, such a complex is most likely to exhibit its effect in vivo without being decomposed for a long time.
- a method for adding a substance such as albumin or polyethylene glycol to the active fragment is described in, for example, “Antibodle s A Labora tatoroy Manu a l” (Col d s p rin g
- a bivalent reactive reagent such as SPDP (Pharmacia), SM PB (Pierce), or EMCS (Dotait) allows the active fragment to be easily bound to albumin or the like. it can.
- the primary structure other than the region (eg, hypervariable region) necessary to react with the TRAF family molecule in the H chain and L chain using the active fragment eg, F Chimeric antibodies can also be obtained by methods such as replacing c with the corresponding primary structure of antibodies from other animal species.
- the novel antibody of the present invention whether a polyclonal antibody or a monoclonal antibody, can be obtained by a known method.
- a polyclonal antibody or a monoclonal antibody can be obtained by a known method.
- the method of obtaining the TRAF family molecule is not limited as long as the TRAF family molecule of the present invention used as an immunogen has a degree of purification that can be used for the production of an antibody.
- the TRAF family molecule used as an immunizing antigen is a small molecule of the TRAF family or a part thereof, that is, a TRAF family molecule consisting of about 10 to 20 amino acid residues or a part thereof, It can be used as an antigen by binding it to a carrier such as Mosyanin (KLH) to the keyhole linker.
- KLH Mosyanin
- the animal immunized with the TRAF family molecule or a part thereof may be any animal other than human, and it is preferable to select and use an animal species that can produce the desired antibody from animals usually used by those skilled in the art.
- a polyclonal antibody can be obtained by purifying the obtained anti-blood plasma.
- methods such as salting out, ion exchange chromatography, affinity chromatography and the like can be combined.
- a monoclonal antibody can be obtained by a method for producing a hybridoma.
- techniques using polyethylene glycol, Sendai virus, electric pulse and the like can be used.
- the antibody can be obtained by using a genetic engineering method.
- mRNA is collected from a hybridoma that produces a spleen cell, a lymphocyte, or a monoclonal antibody against one molecule of the TRAF family or a part thereof of an animal immunized with the TRAF family molecule of the present invention or a part thereof.
- a cDNA library is prepared based on this.
- An antibody is expressed by the cDNA library.
- a clone producing a reactive antibody is obtained from the cDNA library by screening and the obtained clone is cultured.
- the desired antibody is extracted from the culture mixture by salting out, ion exchange chromatography, affinity chromatography, etc. It can be purified by a combination of these methods.
- the antibody of the present invention can be used for detecting the TRAF family molecule of the present invention or a part thereof present in a body fluid or a tissue. Further, the antibody is used for preparing an antibody column used for purifying one molecule of the TRAF family of the present invention or a part thereof, and detecting the one molecule of the TRAF family or a part thereof in each fraction. Can be used.
- the recombinant vector and the transformant of the present invention are characterized by containing all or a part of the gene encoding one TRAF family molecule. These can be produced by various methods as shown in Examples 1, 4, 5 and 7. As a host for the transformant, any of bacteria such as E. coli, yeast, and animal cells can be used.
- these uses may be, for example, the production of all or part of the TRAF 5 molecules as shown in Examples 4 and 5, that is, the method for producing the TRAF family molecules of the present invention.
- the TRAF5 gene may be used to obtain all or part of it in large amounts.
- the transformant of the present invention is cultured to perform gene amplification and expression.
- the culture is recovered, and if necessary, operations such as concentration, solubilization, dialysis, and various types of chromatography are performed to purify the TRAF family molecule of the present invention.
- Purification methods include salting out, ultrafiltration, isoelectric focusing, gel filtration, electrophoresis, ion exchange chromatography, hydrophobic chromatography, antibody chromatography, and other various affinity methods. There are monochromatography, chromatofocusing, adsorption chromatography, reverse phase chromatography, and the like, which may be appropriately selected. As detailed in the examples, purification by affinity chromatography using LT-1] 3R and CD30 or affinity chromatography using the antibodies of the invention is preferred.
- one molecule of the TRAF family to be produced may be produced in a transformant as a fusion peptide with another polypeptide.
- an operation of cutting out the TRAF family molecules by treatment with a chemical substance such as bromocyan or an enzyme such as a protease is added.
- the antisense polynucleotide of the present invention includes all nucleotides consisting of a plurality of nucleotides consisting of bases, phosphates, and sugars, including those not naturally occurring. Typical examples are DNA and mRNA.
- One use of the antisense polynucleotide of the present invention is as a research polynucleotide probe for examining the presence of a gene encoding a TRAF family molecule and its expression status.
- Another use of the antisense polynucleotide of the present invention is to regulate the expression of one TRAF family molecule. Since antisense polynucleotides are expected to hybridize to DNA encoding one molecule of the TRAF family or mRNA encoding one molecule of the TRAF family to promote or suppress the expression of TRAF family molecules, TRAF family molecules It can be used as a therapeutic agent for signal transduction-related diseases in which is involved or LT-1) 3R-mediated signal. That is, an antisense drug is prepared from the polynucleotide or a derivative thereof. It is possible to develop.
- a method of regulating the expression of a protein using a polynucleotide containing a complementary nucleotide sequence of DNA or mRNA encoding the protein is called an antisense method, and many researchers are currently conducting research. Technology.
- a polynucleotide having a sequence complementary to the sequence of the translation initiation codon, the ribosome binding site, the cabling site, and the splice site can be expected to have a high expression suppression effect (see “Cancer and Chemotherapy, Vol. 20, No. 13”). 1899-1907 p.).
- the antisense polynucleotide of the present invention which is a gene encoding a TRAF family molecule or the vicinity of a translation initiation codon of mRNA for the gene, a ribosome binding site, a cabling site, and a splice site are complementary. Those containing a unique sequence are expected to have a high expression regulating effect.
- the antisense polynucleotide preferably has a length of about 16 to 30 bases for use in regulating expression.
- the polynucleotide and the antisense polynucleotide of the present invention comprise a sense polynucleotide.
- the oligonucleotide can express the TRAF family molecule of the present invention, the three-dimensional structure of the antisense polynucleotide is limited so long as it can hybridize to its complementary polynucleotide (sense polynucleotide).
- sense polynucleotide complementary polynucleotide
- polynucleotides whose functions are similar to those of naturally occurring polynucleotides are similar to those of naturally occurring polynucleotides.
- the derivative is preferably a derivative having at least one of increased nuclease resistance, tissue selectivity, cell permeability, and binding strength, and a particularly preferred polynucleotide derivative has a phosphorothioate bond. It is known that the derivative has a skeletal structure.
- the polynucleotide of the present invention and derivatives thereof also include derivatives having these functions or structures.
- some derivatives such as a methylphosphonate type and a phosphorothioate type, can be synthesized using a chemical synthesizer (eg, Perkin Elmer Japan 3394).
- the target polynucleotide can also be obtained by performing the operation according to the instructions attached to the chemical synthesizer, and purifying the obtained synthetic product by an HPLC method using reverse phase chromatography or the like. Derivatives can be obtained.
- (I ZM) described in the above sequence means either I or M.
- the amino acid-encoding nucleotide sequence cannot be determined in one way due to degeneracy (for example, Ala has four possible cases: GCA, GCG, GCC, and GCT).
- the synthesis mode at the time of was selected as GCX (X is A, G, (including any of:, T)), and a mixture of oligo DNA primers corresponding to the selected amino acid sequence was prepared.
- Fig. 6 Here, Figure 6 (1) shows the 256 primers on the sense side, and Figure 6 (2) shows 768 primers on the antisense side. Further, as shown in Fig. 6, each primer contained an EcoRI site.
- a 20.25 (ATC CTIB 208), a mouse B cell lymphoma, was cultured in 25 cm 2 flasks.
- RNAZ01B registered trademark, manufactured by Cosmo Bio
- the reaction was repeated 40 times in a cycle of "45: for 2 minutes, followed by 72 for 1 minute, and then 94 for 1 minute".
- the point to be noted in this reaction is that the annealing temperature was set as low as 45 to make it possible to pick up even those with the lowest possible homology.
- the reaction was carried out overnight at 14 to obtain a ligation mixture.
- ⁇ ⁇ Transformation was performed using a 1 uescript cloning kit. 1) To 5 ⁇ l of the cell suspension on ice, 2 ⁇ l of 0.5 ⁇ / 3 mercaptoethanol and the ligation mixture prepared in 4) were added and left for 30 minutes. After that, they were left in a water bath at 42 for 30 seconds and then on ice for 20 minutes. 450 1 of SOC medium was added and incubated at 225 rpm for 1 hour at 37.
- DNA sequencing was performed using the DNA sequencer model 373 manufactured by Company I, using the dye terminator method.
- the cDNA library is available from Uni-ZAP (registered trademark, manufactured by Stratagene) c DNA library kit (manufactured by Stratagene) and Po1y (A) quick mRNA isolation kit (Stratagene) Was constructed according to the respective instruction manual.
- RNA and cDNA libraries can be prepared by referring to the protocols described in the following books. "Molec u l ar C lon Ing 2 nd E d io t io n", Chapter 8, "Biomanual Series 2 Preparation of Gene Library", pp. 33-40 and 95-106 (Yodosha).
- Hybridization conditions were the conditions described in “Cell Engineering Experiment Protocol”, pp. 57-65 (Shujunsha, 1991). 1) using the random primer labeling kit (Takara Shuzo) and [ ⁇ one 32 P] ATP (Amersham) and the resulting P CR product 7. performs label 32 P, which DN A A probe was used.
- the solid portion is the TRAF domain (positions 342 to 558 of the amino acid sequence of TRAF 5), and the vertical line is the leucine zipper motif (amino acid of the TRAF 5 molecule).
- the hatched portion indicates the Zn finger motif (positions 11 to 250 of the amino acid sequence of TRAF 5 molecule), and the hatched portion indicates the RI NG finger motif (TRAF 5 From position 45 to position 85 of the amino acid sequence).
- TRAF 5 The tissue in which TRAF 5 was expressed was examined as follows.
- RNAZ01B The tissues of mouse brain, thymus, lung, liver, spleen, heart, stomach and adrenal gland were extracted, and each total RNA was extracted using RNAZ01B.
- RNA was prepared using a Pol y (A) quick mRNA isolation kit (Stratagene) according to the same protocol as 9 in Example 1.
- Example 4 The DNA probe prepared in 10.1) of Example 1 was used as the 32 P-probe.
- the hybridization operation was performed under the conditions of high stringency according to “Molecuar Cloning AL aboratory iVI anua 1 2nd Edition” p. 7. 39—7.52. The result is shown in figure 2.
- 28 S indicates a position of 4.9 kb, and 183 indicates a position of 1.9 kb.
- an mRNA band was observed at 2.2 kb (indicated by an arrow), confirming the expression of the TRAF5 gene.
- TNF-R1 TNF-R2, CD40, LT-1] 3R
- GST glutathione-S-transferase
- TRAF5 was translated in vitro using Invitrotranscriptionan dtranslationsystem (TNT, manufactured by Alomega) according to the attached instructions. It was confirmed by electrophoresis that the generated TRAF 5 in Vitro translation was labeled with 35 S-methionine.
- TNT Invitrotranscriptionan dtranslationsystem
- the gel was dried and exposed to X-ray film.
- the results are shown in Figure 3.
- the lane of Invitropro is the lane of the invitrotranslation product.
- the names of the various fusion proteins used are entered in each lane.
- a band corresponding to about 50 kD of TRAF 5 molecules was detected when reacted with the LT-R GST fusion protein. That is, it was found that 5 molecules of TRAF were associated with LTR.
- Immunoprecipitation western blot confirmed the association of the TRAF 5 molecule with LT- / 9R.
- HA epitopes influenza virus hemagglutinin epitopes
- Oligonucleotides corresponding to 9 amino acids of HA epitope were synthesized. That is, the following formula (1) was synthesized as a sense polynucleotide, and the following formula (2) was synthesized as an antisense polynucleotide using a DNA synthesizer.
- pHAK I Tneo was treated with EcoRI and subcloned with the TRAF5 gene amplified by PCR.
- EcoRI By the treatment of EcoRI, introduction of TRAF5 into pHAK I Tneo is better than in the case of introducing TRAF5 ⁇ gene directly into pMKITNeo.
- COS 7 cells ATCC CR L- 1 6 5 1
- 2 X 1 0 and 6 pairs
- 5 ⁇ g pHAK I Tneo - TRAF 5 gene and pc DNA 1- LT-) 3R LT- / 3R-introduced vectors were transiently introduced using the DE AE-dextran method (Pharmacia).
- Cell lysates include 0.1% NP-40, 5 OmM HEPES (pH 7.4), 25 OmM NaCl, 10% glycerol, 2 mM EDTA, 1 mM PMSF, 2 / ig gm1 aprotinin , 2 ⁇ g Zm 1 ⁇ pstatin A and 2 ⁇ g A solution containing / m 1 leptin was used.
- TRAF 5-LT- ⁇ R complex was immunoprecipitated with the solution in which the cells were lysed using an anti-LT-) 3R antibody.
- Block Ace (Dainippon Pharmaceutical Co., Ltd.) was added to the membrane, and blocking was performed for 1 hour at room temperature.
- the membrane was washed with PBS (pH 7.4) containing 0.05% Tween 20 for 10 minutes, and then 10 g of goat anti-HA antibody (manufactured by Behringer) was added. After adding in step 1 and reacting at room temperature for 1 hour, washing with Tween PBS for 10 minutes was repeated three times.
- FIG. 4 shows the results.
- NGS is a lane of goat serum
- Anti-LT-] 3R is a lane of a sample obtained by treating the immunoprecipitate with a sample buffer for reducing SDS-PAGE.
- a band of the HA—TRAF 5 molecule is observed at about 60 kD in the immunoprecipitated antibody with the anti-LT-1; 3R antibody.
- TRAF 5 molecule transmits to the nucleus of cells by examining the activation of NF- ⁇ B DNA binding.
- NF- K was DNA binding ability temper Baie B.
- Fig. 5 shows the results.
- lanes 1 to 5 correspond to the above expression patterns 5 to 5.
- the band indicated by “B ⁇ ” indicates NF- ⁇ B bound to the DNA probe for detection.
- FIG. 5 when the TRAF 5 molecule is expressed, NF- ⁇ B is detected by binding to the DNA probe. From this, it can be seen that induces activation of DN A binding TRAF 5 expression of molecules NF-? Kappa B.
- NF-KB can be induced only by expression of LT-R, but when this is added by about 10 times the amount of amino acids 233 to 558 of the TRAF 5 molecule, a deleted protein, is added. Activation was found to be suppressed. That is, the DNA binding activity of NF- / cB can be suppressed by excessive administration of the 233 to 558 portion of the amino acid SB sequence of 5 TRAF molecules. This indicates that it is possible to control signal transduction by adjusting five TRAF molecules.
- the following two peptides which are partial sequences of five TRAF molecules, were synthesized using a peptide synthesizer.
- Sequence 2 14-mer peptide of Cys Tyr Ser Gly Lys Leulie Trp Lys Val Thr Asp Tyr Arg (CYSGKL I WKVTDYR) from position 401 to position 414 of 5 TRAF molecules.
- Antibodies were prepared independently for each of the peptides prepared in 1. by the following procedure.
- the serum was further subjected to salting out with 40% saturated ammonium sulfate, and an IgG fraction (polyclonal antibody) was obtained by affinity chromatography using Protein A Sepharose (manufactured by Pharmacia). 270 mg of polyclonal antibody was obtained from 5 Oml of serum.
- the titer of the polyclonal antibody was measured by ELISA in the following manner.
- Antigen solution (peptide of sequence 1 and peptide of sequence 2) 25 g Zm each 1 was dispensed into wells of a 96-well ELISA plate (Xenobind, manufactured by Xenopore) in 50 ⁇ l wells, and the mixture was allowed to stand at 4 ° C for 4 hours.
- Block Ace manufactured by Dainippon Pharmaceutical Co., Ltd.
- distilled water was dispensed into each well at 200 ⁇ l / well, blocking was performed, and the mixture was allowed to stand at room temperature for 2 hours.
- FIG. 7 is a graph showing the results of ELISA of the polyclonal antibody against the peptide in column 1
- FIG. 8 is a graph showing the results of ELISA of the polyclonal antibody against the peptide of sequence 2.
- the horizontal axis indicates the concentration of the added polyclonal antibody
- the vertical axis indicates the A490 value.
- the peptide of sequence 1 represents the result of ELISA of a polyclonal antibody obtained by immunizing two egrets. The addition of the antibody increases the A490 value, indicating that the polyclonal antibody has reacted with the antigen.
- cDNA library was carried out in the same manner as in Example 1, 9. However, instead of the mouse monocyte cell line J774A.1 cell and Uni-ZAP (registered trademark) cDNA library kit (Stratagene), human HLTV-1 was The transfected HAT109 cells (obtained from Hiroshi Yoshida of the Institute of Medical Science, The University of Tokyo) and a human gt11 cDNA library kit (Stratagene) were used.
- the cDNA library prepared in 1 was screened using the plaque hybridization method (see “Cell Engineering Experiment Protocol”, pp. 57-65). As a result, 19 positive clones were obtained. All of these clones were subjected to DNA sequencing, and the nucleotide sequence of each clone was determined. As a result, it was found that the 19 clones were fragments of one full-length gene.
- nucleotide sequence of the human TRAF5 gene was determined.
- the nucleotide sequence is shown as SEQ ID NO: 4 in the sequence listing.
- the amino acid sequence of human TRAF5 is shown in SEQ ID NO: 3 in the sequence listing.
- the transformant Escherichia coli containing the longest clone was transferred to the Institute of Biotechnology, National Institute of Advanced Industrial Science and Technology ( ⁇ 305 It was deposited on February 14, 1997 at Tsukuba Guro 1-chome, Ibaraki Pref., Japan (Deposit No. ⁇ ERM BP-5821).
- information obtained from other clones was obtained for parts shorter than the full length.
- cells of BJ AB (Bakit's lymphoma), HEK293 (human fetal cell line), ME180 (cervicalcarcinoma) and FDC-11 (folliculardendritic cells) were obtained as follows. Was recovered and dissolved. 1 ⁇ 10 6 cells were used for each. Cell lysates, 50 mM T ris- HC 1, 1 50 mM Na C l, 1% NP- 40, 5 OmM ® one Doasetoami de, 2mM Mg C 1 2, 2 mM C a C 1 2, 0. 1 % N a N 3, 1 mM EGTA, 1 mM EDTA, 1 mM N a 3 V0 4, a 1 mM N a F. 100 ⁇ l of the cell lysate was added to the pellet of each cell, and the cells were lysed by vigorous stirring.
- the nitrocellulose membrane was immersed in Block Ace (Dainippon Pharmaceutical Co., Ltd.), left for 1 hour, and blocked. Thereafter, the plate was washed twice with 0.05% Tween 20 PBS for 5 minutes.
- Anti-mouse TRAF5 antibody was diluted with PBS to 1 ⁇ gZm 1, added to the membrane, and allowed to react at room temperature for 2 hours. Thereafter, the plate was washed three times for 5 minutes with 0.05% Tween 2 OZPBS.
- TRAF 5 was found to associate with CD30, and both TRAF 2 and TRAF 3 were associated with both CD30 and LT-13R.
- mock indicates cells into which vector-plasmid into which nothing has been inserted has been introduced.
- TRAF 1 TRAF 2, TRAF 3, TRAF 4, and TRAF 5
- Table 1 summarizes the functions and the structural features of the known knowledge and the results obtained in Example 3 and Example 5 in combination.
- + indicates that the feature is provided
- 1 indicates that the feature is not provided
- ND indicates that any is unknown.
- TRAF family molecules of the present invention are useful for elucidating the functions of the molecules of the TNF-R family. Since TNF-R family molecules and TNF are important groups of molecules that trigger intracellular differentiation, proliferation, and death, the use of TRAF family molecules and their elucidation to improve the immune system It is thought that this will lead to elucidation of the mechanisms of differentiation, cancer and apoptosis.
- TRAF family molecules of the present invention are useful as elucidation of signal transduction from LT1 / 3R and as an immune response regulator of LT1 / 3 signal.
- the antibodies of the present invention enable detection of TRAF family molecules of the present invention present in body fluids and tissues.
- the antibody makes it possible to prepare an antibody column used for purifying the TRAF family molecule of the present invention, and to detect a single molecule of the TRAF family in each fraction.
- the active fragment of the antibody of the present invention enables the production of a chimeric antibody.
- a gene encoding the TRAF family molecule of the present invention and a polynucleotide comprising the base sequence of the antisense strand of the gene, a part thereof, and a derivative thereof are used to form a TRAF family molecule in a tissue or a cell. Research and diagnostic polynucleotide probes for examining the presence of the coding gene and its expression status are provided.
- a polynucleotide comprising the antisense strand base sequence of a gene encoding a TRAF family molecule of the present invention, a part thereof and a derivative thereof regulates the expression of one molecule of the TRAF family. It is possible. That is, the TRAF family molecule and its derivative provide a therapeutic agent for a signal transduction disease involving one TRAF family molecule or a disease involving a signal mediated by LT-i3R or CD30. . That is, an antisense drug can be developed from the polynucleotide or a derivative thereof.
- Gin Asn Ser Gly Asn Ser lie Ser Leu Asp Phe Glu Pro Asp Thr Glu
- Gin Lys Glu Ser Lys lie Gin Gin Leu Ala Glu Thr Val Lys Lys Phe
- Lys Gin Arg lie Thr Gin Leu Glu Ala Ser Asp Gin Arg Leu Val Leu
- Sequence type nucleic acid
- AGC TTC AAA AGG CCA GAT GGC GAG ATG AAC ATT GCC TCT GGC TGT CCC 1891
- Gin Lys Glu Ser Lys lie Gin Gin Leu Ala Glu Thr lie Lys Lys Leu
- Lys Gin Lys lie Thr Leu Leu Glu Asn Asn Asp Gin Arg Leu Ala Val
- Sequence type nucleic acid
- GCCGTGGACT TAACTGACCT GGAGGATCTC TAGTCACTGT TATGGGGTGA TAAGAGGACT 1800
- Sequence type nucleic acid
- Sequence type nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97903599A EP0882790A4 (en) | 1996-02-22 | 1997-02-24 | MOLECULE OF THE FAMILY OF TRANSFER GENES F, POLYNUCLEOTIDE CODING FOR THIS MOLECULE, AND ANTIBODIES ACTIVE AGAINST THIS MOLECULE |
US09/138,277 US6426403B1 (en) | 1996-02-22 | 1998-08-18 | TRAF family molecules, polynucleotides encoding them, and antibodies against them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3467496 | 1996-02-22 | ||
JP8/34674 | 1996-02-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/138,277 Continuation-In-Part US6426403B1 (en) | 1996-02-22 | 1998-08-18 | TRAF family molecules, polynucleotides encoding them, and antibodies against them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997031110A1 true WO1997031110A1 (fr) | 1997-08-28 |
Family
ID=12420982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/000512 WO1997031110A1 (fr) | 1996-02-22 | 1997-02-24 | Molecule de la famille des genes de transfert f, polynucleotide codant pour cette molecule et anticorps actif contre cette molecule |
Country Status (3)
Country | Link |
---|---|
US (1) | US6426403B1 (ja) |
EP (1) | EP0882790A4 (ja) |
WO (1) | WO1997031110A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001079279A1 (fr) * | 2000-03-27 | 2001-10-25 | Shanghai Biowindow Gene Development Inc. | Nouveau polypeptide, facteur humain associe au recepteur du facteur de necrose tumorale 16, et polynucleotide codant pour ce polypeptide |
WO2001092319A1 (en) * | 2000-05-24 | 2001-12-06 | Shanghai Biowindow Gene Development Inc. | A NOVEL POLYPEPTIDE-HOMO TNF α RECEPTOR 19.68 AND POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE |
EP1119580A4 (en) * | 1998-10-06 | 2002-01-16 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF EXPRESSION OF FACTORS ASSOCIATED WITH TUMOR NECROSIS FACTOR RECEPTOR (TRAF) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0915155A4 (en) * | 1996-04-11 | 2001-12-12 | Mochida Pharm Co Ltd | NEW SIGNAL TRANSFER PROTEIN. |
AU2002241570A1 (en) * | 2000-10-24 | 2002-06-18 | Curagen Corporation | Human proteins, polynucleotides encoding them and methods of using the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741667A (en) * | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
WO1996020723A1 (en) * | 1994-12-30 | 1996-07-11 | Brigham & Women's Hospital | Controlling traf-mediated signals |
WO1996028568A1 (en) * | 1995-03-13 | 1996-09-19 | The Regents Of The University Of Michigan | Cd40 binding compositions and methods of using same |
-
1997
- 1997-02-24 EP EP97903599A patent/EP0882790A4/en not_active Withdrawn
- 1997-02-24 WO PCT/JP1997/000512 patent/WO1997031110A1/ja not_active Application Discontinuation
-
1998
- 1998-08-18 US US09/138,277 patent/US6426403B1/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
ISHIDA TK, TOJO T, AOKI T, KOBAYASHI N, OHISHI T, WATANABE T, YAMAMOTO T, INOUE J: "TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 93., 1 September 1996 (1996-09-01), US, pages 9437 - 9442., XP002129048, ISSN: 0027-8424, DOI: 10.1073/pnas.93.18.9437 * |
NAKANO H, ET AL.: "HUMAN TNF RECEPTOR-ASSOCIATED FACTOR 5 (TRAF5): CDNA CLONING, EXPRESSION AND ASSIGNMENT OF THE TRAF5 GENE TO CHROMOSOME 1Q32", GENOMICS, ACADEMIC PRESS, SAN DIEGO., US, vol. 42, 1 January 1997 (1997-01-01), US, pages 26 - 32, XP002948963, ISSN: 0888-7543, DOI: 10.1006/geno.1997.4697 * |
NAKANO H, ET AL.: "TRAF5, AN ACTIVATOR OF NF-KAPPAB ANDPUTATIVE SIGNAL TRANSDUCER FOR THE LYMPHOTOXIN-BETA RECEPTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271, no. 25, 21 June 1996 (1996-06-21), US, pages 14661 - 14664, XP002948962, ISSN: 0021-9258, DOI: 10.1074/jbc.271.25.14661 * |
ROTHE M., ET AL.: "A NOVEL FAMILY OF PUTATIVE SIGNAL TRANSDUCERS ASSOCIATED WITH THE CYTOPLASMIC DOMAIN OF THE 75 KDA TUMOR NECROSIS FACTOR RECEPTOR.", CELL, CELL PRESS, US, vol. 78., no. 04., 26 August 1994 (1994-08-26), US, pages 681 - 692., XP000607783, ISSN: 0092-8674, DOI: 10.1016/0092-8674(94)90532-0 * |
See also references of EP0882790A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1119580A4 (en) * | 1998-10-06 | 2002-01-16 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF EXPRESSION OF FACTORS ASSOCIATED WITH TUMOR NECROSIS FACTOR RECEPTOR (TRAF) |
US6399297B1 (en) | 1998-10-06 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs) |
WO2001079279A1 (fr) * | 2000-03-27 | 2001-10-25 | Shanghai Biowindow Gene Development Inc. | Nouveau polypeptide, facteur humain associe au recepteur du facteur de necrose tumorale 16, et polynucleotide codant pour ce polypeptide |
WO2001092319A1 (en) * | 2000-05-24 | 2001-12-06 | Shanghai Biowindow Gene Development Inc. | A NOVEL POLYPEPTIDE-HOMO TNF α RECEPTOR 19.68 AND POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE |
Also Published As
Publication number | Publication date |
---|---|
EP0882790A1 (en) | 1998-12-09 |
US6426403B1 (en) | 2002-07-30 |
EP0882790A4 (en) | 2001-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0368684B1 (en) | Cloning immunoglobulin variable domain sequences. | |
US6143559A (en) | Methods for the production of chicken monoclonal antibodies | |
WO1999014327A2 (en) | Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer | |
JPH07133298A (ja) | ヒトIL−2レセプターγ鎖分子 | |
WO1998022510A9 (en) | Methods for the production of chicken monoclonal antibodies | |
WO1997031110A1 (fr) | Molecule de la famille des genes de transfert f, polynucleotide codant pour cette molecule et anticorps actif contre cette molecule | |
AU710551B2 (en) | Nucleic acid encoding a nervous tissue sodium channel | |
JPWO2019168176A1 (ja) | 抗インテグリンα11モノクローナル抗体、およびその利用 | |
JP3288716B2 (ja) | ヒト接着分子オクルディン | |
US5871916A (en) | ECDN protein and DNA encoding the same | |
JP2002514897A (ja) | Lyst1およびlyst2の遺伝子組成物ならびに使用方法 | |
US20020102551A1 (en) | Nope polypeptides, encoding nucleic acids and methods of use | |
WO1998007737A1 (en) | Method for determining expression of aberrant forms of apc protein | |
AU776063B2 (en) | Compositions and methods for the treatment of tumor | |
US20020146707A1 (en) | Cardiotrophin-1 compositions and methods for the treatment of tumor | |
JP3739445B2 (ja) | Ecdn蛋白質およびそれをコードするdna | |
WO2003076622A1 (en) | PRESYNAPTIC PROTEIN p120 | |
JP2997770B2 (ja) | ウシ由来c−Kitタンパク質に対するモノクローナル抗体とそれを用いた細胞分離法 | |
JPH07145197A (ja) | Ets転写因子 | |
WO1999057269A1 (fr) | Gene hrpi humain | |
JPWO2003038097A1 (ja) | 脳に存在するユビキチン特異的プロテアーゼ及びそれをコードするdna | |
JPH1180196A (ja) | LckSH3ドメイン結合蛋白質及びそれをコードするDNA | |
JPH11217398A (ja) | 新規なrna転写制御因子 | |
JPH10257882A (ja) | モノクローナル抗体の製造方法 | |
JP2000504211A (ja) | デプレニル誘導性タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09138277 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997903599 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997903599 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997903599 Country of ref document: EP |